DayTwo Secures $31M Series B Funding to Advance Food-Based Therapies for Chronic Disease Management

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 26, DayTwo, based in Tel Aviv, Israel, announced the completion of a $31 million Series B financing round. The proceeds will be used to develop next-generation products for the treatment of gastrointestinal disorders and to support market expansion. The round was co-led by aMoon Fund and Ofek Ventures, with participation from existing investors Seventure Partners and Johnson & Johnson. With this latest infusion, DayTwo’s total fundraising has reached $48 million.

DayTwo, established in August 2015, is a developer of a microbiome health management platform designed to provide users with personalized and actionable recommendations. By predicting how an individual’s gut microbiota responds to different food combinations, the company leverages food as a therapeutic intervention to help patients manage chronic diseases and maintain healthy blood glucose levels.

DayTwo’s dietary therapy, developed by Professor Eran Segal and initially published in the prestigious biological journal *Cell* in 2015, demonstrates how gut microbiota and other clinical parameters can enable personalized dietary interventions to successfully balance postprandial glucose responses. DayTwo’s proprietary platform provides users with personalized, actionable guidance on selecting specific foods and meals to stabilize their blood glucose levels. DayTwo’s glycemic control solution is more effective than existing diabetes medications and offers an effective treatment for type 2 diabetes and prediabetes.

“DayTwo possesses an actionable microbiome platform. Our cutting-edge technology and seasoned researchers have positioned DayTwo at the forefront of this field,” said Lihi Segal, CEO and Founder of DayTwo. “Building on this foundation, DayTwo has secured this round of financing to launch food-based therapeutics, addressing the substantial clinical needs of patients with type 2 diabetes in the United States.”

Yahal Zilka, Managing Partner at Ofek Ventures, said, “I am excited to bring DayTwo to the United States, where it has the potential to improve the lives of more than 100 million people with diabetes and prediabetes.”

“DayTwo has accelerated our management of chronic diseases,” commented an MBA and Executive Partner at aMoon Fund. “I have personally witnessed the adverse effects of metabolic disorders on patients, and I am highly enthusiastic about DayTwo’s research findings. I have seen firsthand the company’s ability to help diabetic patients achieve precise blood glucose control through dietary interventions.”

Irit Poraz, Chief Nutritionist at Clalit, stated, “The era of using food as medicine begins here, with DayTwo pioneering actionable microbiome solutions.”

In addition, DayTwo is collaborating with multiple clinical institutions, including the Weizmann Institute of Science, the Israel Diabetes Association, the Joslin Diabetes Center, and Johnson & Johnson Pharmaceutical Companies.

aMoon Fund is a venture capital fund founded by Marius Nacht and Dr. Yair Schindel in 2016, headquartered in HaMerkaz, Israel. The fund primarily invests in early-stage startups in the biopharmaceutical and digital health sectors.

Seventure Partners, established in 1997, is one of Europe’s leading venture capital firms. The firm primarily focuses on two sectors: digital technologies and life sciences. As of December 31, 2016, it managed €660 million in assets and comprised 15 investment professionals with strong track records and deep expertise in technology, entrepreneurship, and various private equity disciplines.

Johnson & Johnson Innovation is a subsidiary of Johnson & Johnson, focusing on providing early-stage research funding, seed funding, and equity investment services to enterprises.

(Compiled by Wang Chan)